| Literature DB >> 36192735 |
Zongfu Pan1,2, Tong Xu1, Lisha Bao3, Xiaoping Hu1, Tiefeng Jin3, Jinming Chen1, Jianqiang Chen1, Yangyang Qian3, Xixuan Lu1, Lu Li4, Guowan Zheng2,3, Yiwen Zhang1,2, Xiaozhou Zou1,2, Feifeng Song1,2, Chuanming Zheng2,3, Liehao Jiang2,3, Jiafeng Wang2,3, Zhuo Tan5,6, Ping Huang7,8, Minghua Ge9,10.
Abstract
Anaplastic thyroid carcinoma (ATC) is an extremely malignant type of endocrine cancer frequently accompanied by extrathyroidal extension or metastasis through mechanisms that remain elusive. We screened for the CREB3 transcription-factor family in a large cohort, consisting of four microarray datasets. This revealed that CREB3L1 was specifically up regulated in ATC tissues and negatively associated with overall survival of patients with thyroid cancer. Consistently, high expression of CREB3L1 was negatively correlated with progression-free survival in an independent cohort. CREB3L1 knockdown dramatically attenuated invasion of ATC cells, whereas overexpression of CREB3L1 facilitated the invasion of papillary thyroid carcinoma (PTC) cells. Loss of CREB3L1 inhibited metastasis and tumor growth of ATC xenografts in zebrafish and nude mouse model. Single-cell RNA-sequencing analysis revealed that CREB3L1 expression gradually increased during the neoplastic progression of a thyroid follicular epithelial cell to an ATC cell, accompanied by the activation of the extracellular matrix (ECM) signaling. CREB3L1 knockdown significantly decreased the expression of collagen subtypes in ATC cells and the fibrillar collagen in xenografts. Due to the loss of CREB3L1, ATC cells were unable to activate alpha-smooth muscle actin (α-SMA)-positive cancer-associated fibroblasts (CAFs). After CREB3L1 knockdown, the presence of CAFs inhibited the growth of ATC spheroids and the metastasis of ATC cells. Further cytokine array screening showed that ATC cells activated α-SMA-positive CAFs through CREB3L1-mediated IL-1α production. Moreover, KPNA2 mediated the nuclear translocation of CREB3L1, thus allowing it to activate downstream ECM signaling. These results demonstrate that CREB3L1 maintains the CAF-like property of ATC cells by activating the ECM signaling, which remodels the tumor stromal microenvironment and drives the malignancy of ATC.Entities:
Keywords: Anaplastic thyroid carcinoma; CREB3L1; Cancer-associated fibroblasts; Collagen; Extracellular matrix
Mesh:
Substances:
Year: 2022 PMID: 36192735 PMCID: PMC9531463 DOI: 10.1186/s12943-022-01658-x
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 41.444
Primers for the different genes
| Gene ID | Forward primer | Reverse primer |
|---|---|---|
| β-ACTIN | ACCTTCTACAATGAGCTGCG | CCTGGATAGCAACGTACATGG |
| CREB3L1 | GGAGAATGCCAACAGGACC | GCACCAGAACAAAGCACAAG |
| COL1A1 | CCCCTGGAAAGAATGGAGATG | TCCAAACCACTGAAACCTCTG |
| COL3A1 | AAGTCAAGGAGAAAGTGGTCG | CTCGTTCTCCATTCTTACCAGG |
| COL4A1 | TGTGGATCGGCTACTCTTTTG | TAGTAATTGCAGGTCCCACG |
| COL5A1 | TCGCTTACAGAGTCACCAAAG | GTTGTAGATGGAGACCAGGAAG |
| COL6A1 | AGGAGTCAAAGGAGCAAAGG | GCATTCACAGCAAGAGCAC |
| P4HA1 | CCCCATTTTGACTTTGCACG | AACACTAGCTCCAACTTCAGG |
| INH1 | ATCTTCCTGGTGCTGTTGAC | TGCTTGCGTGTTCCTATCAG |
| LEPRE1 | TCACTGTCTTCAAAGCCCTC | GATGAGAGTAGGAAAAGTAGAGG |
Clinicopathological features of 234 patients with thyroid cancer
| Variables | Stratification | CREB3L1 expression | ||
|---|---|---|---|---|
| Low ( | High ( | |||
| Age (years) | < 55 | 134 | 64 | 0.498 |
| ≥ 55 | 27 | 9 | ||
| Gender | Men | 39 | 13 | 0.356 |
| Women | 122 | 60 | ||
| Bilaterality | Unilateral | 131 | 54 | 0.265 |
| Bilateral | 30 | 19 | ||
| Tumor number | Solitary | 114 | 47 | 0.406 |
| Multiple | 47 | 26 | ||
| Maximal tumor diameter | < 1 cm | 36 | 16 | 0.847 |
| > 4 cm | 12 | 4 | ||
| 1–4 cm | 113 | 53 | ||
| Capsule invasion | Extracapsular | 56 | 29 | 0.758 |
| Absent | 87 | 36 | ||
| Present | 18 | 8 | ||
| Intrathyroidal dissemination | Absent | 137 | 67 | 0.228 |
| Present | 24 | 6 | ||
| T staging | pT1 | 83 | 35 | 0.89 |
| pT2 | 17 | 7 | ||
| pT3 | 42 | 20 | ||
| pT4 | 19 | 11 | ||
| N staging | pN0 | 59 | 29 | 0.718 |
| pN1a | 54 | 26 | ||
| pN1b | 48 | 18 | ||
| M staging | M0 | 159 | 72 | 1 |
| M1 | 2 | 1 | ||
| Total thyroidectomy | Not done | 127 | 49 | 0.077 |
| Done | 34 | 24 | ||
| Lymph node dissection | Not done | 9 | 6 | 0.636 |
| Done | 152 | 67 | ||
Fig. 1Expression of CREB3L1 in thyroid cancer and its clinical prevalence. A The expression of CREB3 family members in thyroid cancer subtypes and normal tissues was analyzed in four integrated datasets. B The relationship between CREB3L1 expression and tumor stage in thyroid cancer was retrieved from the GEPIA database. C Overall survival (OS) analysis of CREB3L1 in thyroid cancer was retrieved from the Kaplan–Meier plot database. D Progression-free survival analysis of CREB3L1 in an independent thyroid cancer cohort. Immunohistochemistry (IHC) staining of CREB3L1 was conducted in tissue microarrays contained 234 PTC samples. E IHC staining were used to analyze CREB3L1 expression in NT, PTC, and ATC tissues. F CREB3L1 expression in different thyroid cancer cell lines was analyzed by western blotting (WB). Data are presented as the mean ± standard deviation (SD). *P < 0.05, **P < 0.01 versus the respective NT, PTC, or ATC
Univariate and multivariate Cox regression analysis of CREB3L1 expression with patient prognosis
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age | 1.311e + 09 (0-inf) | 0.9968 | ||
| Gender | 1.896 (0.686–5.241) | 0.2174 | ||
| T staging | 2.629 (1.417–4.876) | |||
| N staging | 1.463 (0.4777–4.483) | 0.5051 | ||
| M staging | 5.443 (1.161–25.52) | |||
| TNM staging | 2.434 (1.542–3.842) | 3.621 (1.388–9.447) | ||
| Maximal tumor diameter | 1.403 (1.072–1.836) | |||
| Lymph node number | 1.003 (0.9068–1.11) | 0.9527 | ||
| Primary neoplasm focus type | 0.2495 (0.05635–1.105) | 0.06745 | ||
| Iodine radiotherapy | 4.005e + 08 (0-inf) | 0.9991 | ||
| Lymph node preoperative scan indicator | 1.496 (0.4241–5.273) | 0.5313 | ||
| History of neoadjuvant treatment | 18.24 (3.976–83.66) | |||
| CREB3L1 expression | 4.831 (1.754–13.3) | 4.979 (1.074–23.08) | ||
HR Hazard ratio
* Statistical significance
Fig. 2CREB3L1 knockdown suppressed the ATC invasion in vitro. A The knockdown or overexpression efficiency of CREB3L1 was analyzed by WB. Cell viability (B), migration (C), and invasion (D) were determined after CREB3L1 knockdown or overexpression in 8505C, CAL62, or BCPAP cells, respectively. Data are shown as the mean ± SD
Fig. 3CREB3L1 knockdown decreased metastasis and tumor growth of ATC in vivo. A Schematic diagram of the experimental procedure. DiI-labeled 8505C cells (red) were implanted into the perivitelline space of each zebrafish. B The zebrafish xenograft model was employed to evaluate the metastatic ability of 8505C cells, after CREB3L1 knockdown. C-D CREB3L1 knockdown slowed tumor growth in nude mice with ATC xenografts. E–F CREB3L1 knockdown inhibited tumor metastasis in nude mice with intravenous injection of 8505C cells. G H&E staining revealed the ATC metastases (dotted-line circle) in the lung tissues. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 NC versus CREB3L1-KD
Fig. 4CREB3L1 is associated with ECM signaling in thyroid cancer. A GSEA determined the enrichment differences of biological processes depending on the CREB3L1 expression. B-C The evaluated activity scores of the extracellular matrix (ECM) and collagen signaling in NT, PTC and ATC samples. D-E The Pearson correlation analysis of CREB3L1 and ECM or collagen signaling. F Immunofluorescence staining of CREB3L1 and fibroblast marker FAP in thyroid cancer samples. G RT-PCR was used to detect the expression of collagen signals after CREB3L1 knockdown. H The expression of COL5A1 was detected, after CREB3L1 knockdown or overexpression in thyroid cancer cell lines. I-J After CREB3L1 knockdown, Masson trichrome staining and IHC staining were used to detect changes in collagen fibril abundance and the expression of α-SMA after CREB3L1 knockdown, respectively. K Immunofluorescence staining of COL5A1 in ATC cell-derived xenografts after CREB3L1 knockdown. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 NC versus CREB3L1-KD
Fig. 5Single-cell RNA-sequencing revealed the role of CREB3L1 and downstream ECM signaling in ATC progression. A The UMAP plot of 16 cell subsets. B Expression, abundance, and positive ratio of CREB3L1 in different cell subsets. C Clustering results of thyroid follicular and cancer cells. D Proportion of different cell subsets in each group. E Expression and distribution of CREB3L1 in thyroid follicular cells and cancer cells. F Gene set variation analysis (GSVA) was used to calculate the activity of the ECM and collagen signaling in each cell. G Trajectory analysis of thyroid follicular and cancer cells. (H) Expression trends of CREB3L1, and the ECM and collagen signaling along the trajectory of ATC formation
Fig. 6CREB3L1 is involved in remodeling the stromal microenvironment of ATC. A Single-cell RNA-sequencing was used to examine the interaction between ATC cell subsets and cells in the tumor microenvironment. B The sphere formation assay was used to detect the growth of 8505C cells mixed with or without CAFs after CREB3L1 knockdown. ***P < 0.001 CAF + NC versus CAF + CREB3L1-KD. C Schematic diagram of the experimental procedure. Equal numbers of DiI-labeled 8505C cells (red) and DiO-labeled CAFs (green) were mixed and implanted into the perivitelline space of each zebrafish. D The zebrafish xenograft model was employed to evaluate the CAF-mediated metastasis of 8505C cells after CREB3L1 knockdown. E Flow cytometry analysis of α-SMA-positive fibroblasts, after co-culture with 8505C cells. *P < 0.05, **P < 0.01 versus the respective CAF + medium, CAF + NC, or CAF + CREB3L1-KD. F Flow cytometry analysis of α-SMA positive fibroblasts in the sphere derived from the mixture of 8505C and CAFs. G Flow cytometry analysis of α-SMA-positive fibroblasts in the lung tissues of mice with ATC pulmonary metastasis. *P < 0.05 NC versus CREB3L1-KD. H Counterstaining of Ki67 and α-SMA with antibodies that specifically reacted with the human (Ki67) and mouse (α-SMA) antigen, respectively. Data are presented as the mean ± SD
Fig. 7Nuclear translocation of CREB3L1 by KPNA2 activates IL-1α expression. A The cytokines changed in the supernatant of 8505C cells (left panel) and co-culture supernatant of 8505C-CAFs (right panel) after CREB3L1 knockdown were detected by human cytokine array. B-C Validation of IL-1α in the supernatant by ELISA kit. D The proportion of α-SMA+ CAFs was analyzed by flow cytometry. CAFs were co-cultured with 8505C cells and were exposed to 1 ng/mL IL-1α for 48 h. *P < 0.05, **P < 0.01 NC versus CREB3L1-KD or CAF + NC versus CAF + CREB3L1-KD. A nucleocytoplasmic separation assay (E) and immunofluorescence (F) were used to detect the localization of CREB3L1 in PTC and ATC cell lines. (G) The expressions of the nuclear transport receptor karyopherin family members were analyzed in four integrated datasets. H Co-immunoprecipitation was used to verify the interaction between CREB3L1 and KPNA2 in different thyroid cancer cells. I WB was used to detect the cytoplasmic and nuclear expression of CREB3L1 after KPNA2 silencing in 8505C cells